文献速递前列腺癌

骨代谢标志物与骨转移性激素敏感性前列腺癌男性总生存:SWOG S1216 三期试验(雄激素剥夺联合或不联合奥利特隆)的子集分析

Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-02-29

SWOG S1216 三期试验预设子集分析,评估骨代谢标志物与骨转移性激素敏感性前列腺癌总生存的关系。在 713 例有基线骨转移且骨标志物可评估的男性中,CICP、CTx 和 PYD 升高与更差总生存显著相关,骨标志物分组可区分不同总生存结局。

要点

  • CICP 升高与总生存显著相关,校正后 HR 1.58(95%CI 1.09–2.29),p<0.02。
  • CTx 升高与总生存显著相关,校正后 HR 1.55(95%CI 1.12–2.15),p=0.008。
  • PYD 升高与总生存显著相关,校正后 HR 1.66(95%CI 1.27–2.217),p=0.0002。

核心结论

  • 在 SWOG S1216 预设子集分析中,骨转移性激素敏感性前列腺癌男性血清骨代谢标志物升高与更差总生存显著相关。
  • 骨标志物水平单独及结合患者和肿瘤特征可识别总生存结局不同的独特亚组。

研究设计与样本

  • SWOG S1216 三期试验的预设子集分析,评估雄激素剥夺联合或不联合奥利特隆。
  • 在骨转移性激素敏感性前列腺癌男性中检测血骨吸收标志物(CTx、PYD)和骨形成标志物(CICP、BAP)。
  • 患者随机分为训练集(n=238)和验证集(n=475)。
  • 训练集用递归分割确定各标志物及组合的二分类切点以定义预后分组,验证集用 Cox 比例风险模型评估标志物对总生存的影响并校正患者和肿瘤特征。

主要发现

  • 1279 例男性中 713 例有基线骨转移且骨标志物可评估,总体人群与骨转移子集的患者特征相似。
  • 校正治疗臂和基线临床变量后总生存 HR(95%CI):BAP 1.31(0.93–1.84),p=0.12;CICP 1.58(1.09–2.29),p<0.02;CTx 1.55(1.12–2.15),p=0.008;PYD 1.66(1.27–2.217),p=0.0002。
  • 标志物升高与治疗之间无交互证据(所有 p>0.2)。
  • 递归分割算法基于骨标志物并校正基线临床变量识别出四组总生存结局不同的患者,中位总生存从 2.3 年(最高风险组)到 7.5 年(最低风险组)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Circulating biomarkers of bone metabolism are significantly associated with overall survival (OS) in men with advanced prostate cancer. In the SWOG S1216 phase III trial, we showed that elevated bone biomarkers are significantly associated with an increased risk of death in hormone-sensitive prostate cancer (HSPC) regardless of the status of bone metastases, identifying three risk groups with differential OS outcomes based on bone biomarker status. Here we report the association of bone biomarkers with OS in men with HSPC and documented skeletal metastases as part of a planned subset analysis of S1216. METHODS: Bone resorption [C-telopeptide (CTx); Pyridinoline (PYD)] and bone formation markers [C-terminal collagen propeptide (CICP); bone alkaline phosphatase (BAP)] were assessed in blood from men with bone metastatic HSPC. Patients were randomly divided into training (n = 238) and validation (n = 475) sets. In the training set, recursive partitioning that maximizes discrimination of OS was used to identify the dichotomous cut-point for each biomarker and for a combination of biomarker split points to define prognostic groups. In the validation set, Cox proportional hazards models were used to assess the impact of biomarkers on OS, adjusted for patient and tumor characteristics. RESULTS: Of 1279 men, 713 had both baseline bone metastases and evaluable bone biomarkers. Patient characteristics were similar between the overall population and the subset with bone metastases. Elevated levels of CICP, CTX, and PYD were strongly prognostic for OS. Hazard ratios (95% CI) for OS adjusted for treatment arm and baseline clinical variables were: BAP-1.31 (0.93, 1.84), p = 0.12; CICP-1.58 (1.09, 2.29), p < 0.02; CTx - 1.55 (1.12, 2.15), p = 0.008; and PYD-1.66 (1.27, 2.217), p = 0.0002. There was no evidence of interaction between elevated biomarkers and treatment (all p > 0.2). Recursive partitioning algorithms identified four groups of patients with differential OS outcomes based on bone biomarkers, adjusted for baseline clinical variables, with median OS ranging from 2.3 years (highest risk group) to 7.5 years (lowest risk group). CONCLUSIONS: In this planned S1216 subset analysis of men with HSPC and bone metastases, elevated serum markers of bone metabolism were significantly associated with worse OS. Bone biomarker levels alone and in combination with patient and tumor characteristics identify unique subsets of men with differential OS outcomes. GOV IDENTIFIER: NCT01809691.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Lara PN, Mayerson E, Gertz E, et al. Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel. Prostate Cancer Prostatic Dis. 2024. PMID: 38424319. doi:10.1038/s41391-024-00813-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。